Notice of Results

RNS Number : 5633L

Genedrive PLC

09 September 2019

 

genedrive plc

("genedrive" or the "Company")

Notice of Results

genedrive plc (LSE: GDR), the near patient molecular diagnostics company, announces it will release its preliminary results for the year ended 30 June 2019 on Thursday, 3 October 2019.

For further details please contact:

genedrive plc		www.genedriveplc.com
David Budd: CEO / Matthew Fowler: CFO		[phone]
Peel Hunt LLP		[phone]
James Steel / Oliver Jackson
Stanford Capital Partners Limited		[phone]
Patrick Claridge / John Howes
Walbrook PR Ltd (Media Relations & Investor Relations)	[phone] or [e-mail]
Paul McManus / Anna Dunphy		[phone] / [phone]

Notes to Editors

About genedrive plc

genedrive plc is a molecular diagnostics company developing and commercialising a low cost, rapid, versatile, simple to use and robust point of need molecular diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. The Genedrive® HCV-ID kit has received CE-IVD Certification and has been launched in Africa and Asia Pacific. genedrive has distribution agreements with subsidiaries of Sysmex Corporation for the distribution of the Genedrive® platform in the EMEA and SE Asia (ex-India), and with ARKRAY Healthcare pvt Ltd for the distribution of the Genedrive® HCV-ID Kit and Genedrive® platform in India. The Company has assays on market for the detection of certain biological targets and has tests in development for tuberculosis (mTB) and Antibiotic Induced Hearing Loss (AIHL).

Further details can be found at: www.genedriveplc.com and www.genedrive.com.

 

END

 

 

NORLFMATMBMMBBL